Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
Clene Inc. (NASDAQ:CLNN)和其全资子公司Clene Nanomedicine Inc.报告了VISIONARY-MS试验的长期开放标签延伸(LTE)的新CNM-Au8®结果 - CNM-Au8治疗在35个月内显示出改善视力和认知的效果[1] - 在LTE期间，接受安慰剂的参与者转换至CNM-Au8显示出显著的改善[8]